CD47 antibody blockade as novel therapy for ovarian and breast cancer
AK Volkmer, SB Willingham, JP Volkmer, SR Tseng, PD Ho, BI Sikic, R Majeti, IL Weissman · Geburtshilfe und Frauenheilkunde · 2014 · Heft 09
Bibliografische Angaben
Zusammenfassung
Introduction: We have identified CD47 as a “don't eat me” signal expressed by cancer cells to escape elimination by the innate immune system. Upon binding to its receptor SIRPalpha on macrophages, CD47 initiates an inhibitory signal that blocks phagocytosis. We have developed a humanized anti-CD47 antibody, Hu5F9-G4 and tested its therapeutic efficacy on ovarian cancer (OC) and breast cancer (BC) in preclinical models. Methods: The efficacy of Hu5F9-G4 on OC was tested first in an in vitro phagocytosis-assay. Next, GFP-luciferase positive OC cells were transplanted into immunodeficient mice and treated with Hu5F…
